Vaccine Therapy in Malaria Treatment Armamentarium: Prospects for Nigerian Children

Aderoyeje TG [1,2*] Erhuanga OG [1]

[1]Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Medical Sciences, Edo State University, Iyamho-Uzairue, Edo State.
[2]Malaria Research Laboratories, Institute of Advanced Medical Research and Training (IAMRAT), College of Medicine, University of Ibadan, Ibadan, Oyo State.
[*]**Correspondence author:** tope_forever@yahoo.com; aderoyeje.temitope@edouniversity.edu.ng; **+234**8077467765

ABSTRACT

Malaria remains a significant public health challenge in Nigeria, particularly among children. Vaccine therapy offers a promising avenue for combating this disease. This review explores the current landscape of malaria vaccine development, evaluates the effectiveness of existing vaccines, and discusses the potential impact of these vaccines on Nigerian children. Also considered are the logistical and socio-economic factors influencing vaccine deployment in Nigeria.

INTRODUCTION

Malaria, primarily caused by the genus *Plasmodium*, involves five species in human infection: *falciparum*, *vivax*, *ovale*, *malariae*, and *knowlesi* [1]. It is a leading cause of morbidity and mortality among Nigerian children. Traditional control measures, such as insecticide-treated nets (ITNs) and antimalarial drugs, have had limited success in eradicating the disease [2]. Vaccine therapy represents a significant advancement in the fight against malaria, offering the potential for long-term immunity and reduction in transmission rates [3].

Current Malaria Vaccines

The RTS,S/AS01 (Mosquirix)
The RTS,S/AS01 (Mosquirix) vaccine, developed by GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative, is the most advanced malaria vaccine to date [4]. Approved by the World Health Organization (WHO) for pilot implementation, RTS,S/AS01 targets the circumsporozoite protein (CSP) of *Plasmodium falciparum* [5]. Clinical trials have shown that the vaccine provides partial protection against malaria, reducing the incidence of clinical malaria by approximately 39% in children aged 5-17 months [6].

The R21/Matrix-M
Another promising candidate is the R21/Matrix-M vaccine, developed by the University of Oxford and the Serum Institute of India. Preliminary results from phase IIb trials in Burkina Faso indicate an efficacy of 77%, which, if confirmed in larger trials, could significantly impact malaria control efforts [7]. This vaccine also targets the CSP and utilizes a novel adjuvant to enhance the immune response [3].

Prospects

Advancement in Vaccine Research
The potential for elucidating other vaccine targets in the plasmodial lifecycle through various experimental and clinical research aims to improve the efficacy and duration of protection offered by malaria vaccines [3]. Next-generation vaccines are exploring multi-antigen approaches and novel adjuvants to enhance the immune response [16]. Additionally, efforts are underway to develop vaccines that provide broader protection against multiple strains of *Plasmodium* [3]. These advancements will undoubtedly offer wider therapy options for the treatment of malaria [17].

Integrated Malaria Control Strategies
The addition of vaccine therapy to the malaria treatment armamentarium should be integrated with other malaria control measures, such as ITNs, indoor residual spraying (IRS), seasonal malaria chemoprevention (SMC), and case treatment (Bhatt et al., 2015). An integrated approach can provide a synergistic effect, reducing the overall impact on malaria transmission and disease burden [10].

Impact on Nigerian Children

Epidemiological Impact
Implementing malaria vaccines in Nigeria could drastically reduce the burden of the disease among children [8]. Given the high transmission rates and the vulnerability of children under five, vaccination could lower the incidence of severe malaria cases, hospital

admissions, and malaria-related deaths [2]. The RTS,S/AS01 vaccine, for instance, is expected to prevent millions of cases if widely administered [9].

Health System Strengthening

Introducing malaria vaccines necessitates strengthening the existing health infrastructure [10]. This includes improving cold chain systems for vaccine storage, training healthcare workers, and establishing efficient delivery mechanisms. Such improvements can have broader benefits for the health system, enhancing the delivery of other vaccines and health services [11].

Challenges and Considerations

Logistical Challenges

Vaccine deployment in Nigeria faces several logistical challenges [12]. These include maintaining the cold chain in remote areas, ensuring consistent vaccine supply, and addressing potential vaccine hesitancy among communities [13]. Strategies to overcome these challenges include leveraging mobile health technologies for tracking and reporting, engaging local leaders to build trust, and integrating malaria vaccines into existing immunization programs [14].

Socio-Economic Factors

Socio-economic factors play a crucial role in the success of vaccination programs [15]. Poverty, limited access to healthcare, and educational disparities can hinder vaccine uptake [10]. Addressing these issues requires a multifaceted approach, including community education, financial incentives for vaccination, and partnerships with non-governmental organizations to reach underserved populations [8].

Conclusion

Vaccine therapy represents a transformative tool in the fight against malaria, with significant potential to improve the health and well-being of Nigerian children [18]. While challenges remain, strategic planning, robust health infrastructure, and community engagement can pave the way for successful vaccine deployment [11]. The continued evolution of malaria vaccines and their integration into comprehensive malaria control strategies offer hope for a malaria-free future in Nigeria [15].

REFERENCES

1. Adebayo, S. B., Afolabi, B. M., Adedokun, B. O., Iwuala, S. O., Osinusi, K., & Salako, L. A. (2013). Rural-urban differences in the risk of severe malaria in Nigerian children. *PLoS ONE*, *8*(5), e60884.
2. Bhatt, S., Weiss, D. J., Cameron, E., Bisanzio, D., Mappin, B., Dalrymple, U., Battle, K. E., Moyes, C. L., Henry, A., Eckhoff, P. A., Wenger, E. A., Briët, O., Penny, M. A., Smith, T. A., Bennett, A., Yukich, J., Eisele, T. P., Griffin, J. T., Fergus, C. A., Lynch, M., Lindgren, F., Cohen, J. M., Murray, C. L., Smith, D. L., Hay, S. I., Cibulskis, R. E., & Gething, P. W. (2015). The effect of malaria control on Plasmodium falciparum in Africa

between 2000 and 2015. *Nature*, *526*(7572), 207-211.

3. Draper, S. J., Sack, B. K., King, C. R., Nielsen, C. M., Rayner, J. C., & Higgins, M. K. (2015). Recent advances in recombinant protein-based malaria vaccines. *Vaccine*, *33*(52), 7433-7443.
4. RTS, S Clinical Trials Partnership. (2015). Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of phase 3, individually randomized, controlled trial. The Lancet, 386(9988), 31-45.
5. World Health Organization. (2021). World Malaria Report 2021. WHO.
6. Agnandji, S. T., Lell, B., Soulanoudjingar, S. S., Fernandes, J. F., Abossolo, B. P., Conzelmann, C., Methogo, B. G. N., Doucka, Y., Flamen, A., Mordmüller, B., Issifou, S., Kremsner, P. G., Sacarlal, J., Aide, P., Lanaspa, M., Aponte, J. J., Machevo, S., Acacio, S., Bulo, H., Sigauque, B., Macete, E., Alonso, P., Abdulla, S., Salim, N., Juma, O., Shomari, M., Shubis, K., Machera, F., Hamad, A. S., Minja, R., Mtoro, A. T., Sykes, A., Ahmed, S., Urassa, H., Ali, A. M., Mollel, E., Tanner, M., Tinto, H., D'Alessandro, U., Sorgho, H., Valea, I., Tahita, M. C., Kabore, W., Ouédraogo, S., Sandrine, Y., Guiraud, I., Ravinetto, R., Van Nguen, P., Menten, J., Lievens, M., Dubois, M. C., Demoitié, M. A., Leach, A., Lievens, M., Thiry, G., Vekemans, J., Carter, T., Villafana, T., Lapierre, D., Ballou, W. R., & Cohen, J. (2011). First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *New England Journal of Medicine*, *365*(20), 1863-1875.
7. Datoo, M. S., Natama, M. H., Some, A., Traore, O., Rouamba, T., Bellamy, D., Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., Soma, R., Sawadogo, S., Sorgho, F., Derra, K., Rouamba, E., Lelay, G., Osei-Kwakye, K., Awuni, D. A., Mpina, M., ... Hill, A. V. S. (2021). Efficacy of a low-dose candidate malaria vaccine, R21/Matrix-M, with or without adjuvant, in Burkina Faso: a phase 2b randomised, controlled trial. *The Lancet*, *397*(10287), 1819-1829. https://doi.org/10.1016/S0140-6736(21)00943-0
8. National Malaria Elimination Programme (NMEP), Nigeria. (2020). National Strategic Plan for Malaria Control in Nigeria 2021-2025. Retrieved from NCDC website
9. Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., Kaslow, D., Njuguna, P., Marsh, K., Bejon, P., & The RTS,S Clinical Trials Partnership. (2016). Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. *New England Journal of Medicine*, *374*(26), 2519-2529.
10. Kamya, M. R., Arinaitwe, E., Wanzira, H., Kakuru, A., Ikilezi, G., Yeka, A., Nankabirwa, J. I., Bigira, V., Kapisi, J.,

.

Makombe, R., Katabira, T., Nasr, S., Greenhouse, B., Dorsey, G., Rosenthal, P. J., & Staedke, S. G. (2020). The impact of malaria control interventions on inequality in Uganda. *Nature Communications, 11*, 4066.

11. Malaria Consortium. (2021). The impact of malaria vaccines on health and development. Retrieved from Malaria Consortium website
12. Gavi, the Vaccine Alliance. (2021). Malaria vaccine implementation program. Retrieved from Gavi website
13. UNICEF. (2020). Vaccine hesitancy: What it means and what we need to know to tackle it. Retrieved from UNICEF website
14. Omoleke, S. A., Ajibola, O., Adebayo, K. O., & Adebisi, Y. A. (2016). A review of the challenges of tackling infectious diseases in Nigeria. *Health, 8*, 910-924.
15. Roll Back Malaria Partnership. (2021). The socio-economic impact of malaria. Retrieved from RBM Partnership website
16. Seder, R. A., Chang, L. J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., ... & Ledgerwood, J. E. (2013). Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science, 341(6152), 1359-1365.
17. Duncan, C. J. A., Hill, A. V. S., & Ellis, R. D. (2021). Can growth arrest-specific protein 6 act as a systemic biomarker for severe malaria? Clinical Infectious Diseases, 73(6), e1334-e1335. World Health Organization. (2020). World Malaria Report 2020. Retrieved from WHO website